COMPANY

Aneuvo

Profile checked Oct 10, 2026

Timeline

Mar 27, 2026 FDA FDA 510(k) clearance: ExaStim® Stimulation System (EXA-001); ExaStim® Stimulation System (EXA-011); ReCure® Electrode Pad (PAD-003); ReCure® Electrode Pad (PAD-013) — K252893, Mar 27, 2026. Applicant at source ↗
Mar 5, 2026 Raise Private equity round — Series C: $22M (total, as published), announced Mar 5, 2026. Source: company release on GlobeNewswire. source ↗

Raised: $22.0M. Last 2 years.

Mar 5, 2026 Private equity round — Series C: $22M (total, as published), announced Mar 5, 2026. Source: company release on GlobeNewswire. source ↗

Mar 27, 2026 FDA 510(k) clearance: ExaStim® Stimulation System (EXA-001); ExaStim® Stimulation System (EXA-011); ReCure® Electrode Pad (PAD-003); ReCure® Electrode Pad (PAD-013) — K252893, Mar 27, 2026. Applicant at approval: Aneuvo. source ↗

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12